You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb10573 |
---|---|
Category | Tools |
Description | HPV16 E7 antibody |
Species/Host | Rabbit |
Clonality | Polyclonal |
Tested applications | FC |
Isotype | IgG |
Immunogen | KLH conjugated synthetic peptide derived from HPV16 E7 protein (41-90/98 aa) |
Concentration | 1mg/ml |
Dilution range | Flow-Cyt=1ug/Test, IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500 |
Form/Appearance | Liquid |
Conjugation | Unconjugated |
MW | 11 kDa |
Target | HPV16 E7 |
UniProt ID | P03129 |
Storage | Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
Buffer/Preservatives | 0.01M TBS(pH7.4) with 1% rAlbumin, 0.03% Proclin300 and 50% Glycerol. |
Alternative names | E7; HPV16 E7 protein; HPV 16 E7 protein; Human Pap Read more... |
Note | For research use only |
Expiration Date | 12 months from date of receipt. |
Filter by Applications
Filter by Reactivity
Hu, Zheng et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy J Clin Invest, 125, 425-436 (2015)
Applications
Reactivity
Gao, Chun et al. The application of CRISPR/Cas9 system in cervical carcinogenesis Cancer Gene Ther, (2021)
Applications
Reactivity
Xiong, Jinfeng et al. E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester) Int J Nanomedicine, 16, 7609-7622 (2021)
Applications
Reactivity
Zhu, Da et al. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy Mol. Ther., 26, 2443-2455 (2018)
Applications
Reactivity
Applications
Reactivity
Immunohistochemical analysis of paraffin-embedded human uterus tissue using HPV16 E7 antibody
IHC-P of human uterus tissue (HPV16 E7 antibody at 1:250)
Immunohistochemical analysis of formalin fixed and paraffin embedded human breast cancer using HPV16 E7 antibody
Representative data from H&E staining and E7 IHC staining at treatment days 0, 12, 18, and 24. The mice were treated with HPV16-E7-T512 using the 3-day interval regimen. n = 3 per group. Scale bars: 80 um.
Filter by Rating